{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000039","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.623921+00:00","generated_at":"2026-05-26T04:49:47.971690+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Q4 2024 net loss $94M; casdatifan shows best-in-class potential in ccRCC","bullets":["Revenue $36M for Q4 2024 ($31M Q4 2023); net loss widened to $94M from $81M.","Cash & marketable securities $992M as of Dec 31, 2024, up from $866M year-end 2023.","Casdatifan monotherapy in IO/VEGFR-TKI experienced ccRCC achieved 30%+ ORR, 9.7-month median PFS (50mg BID).","Phase 3 PEAK-1 (casdatifan + cabozantinib vs cabo in post-IO ccRCC) expected to initiate Q2 2025.","Domvanalimab/zimberelimab Phase 3 STAR-221 top-line data for 1L upper GI cancers expected 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000039","json":"https://secwatch.observer/filing/0001724521-25-000039.json","markdown":"https://secwatch.observer/filing/0001724521-25-000039.md","text":"https://secwatch.observer/filing/0001724521-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000039/0001724521-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000039/rcus-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:49:47.971690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}